Vermillion Posts $413K in Q3 Revenues, Inks New Deal with Quest

The company also announced a new agreement with Quest Diagnostics which will give Vermillion $50 upfront for each OVA1 test performed and a royalty of 33 percent.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories